[03/22/20]
Posted on March 22, 2020 in COVID-19 Daily Updates
Published by: Hall Render
Sunday, March 22 Recap Note – We believe this is the most up-to-date information available at this time, but it is subject to change as circumstances warrant. Also, all finalized resources can be found on the COVID-19 Resource Center page of Hall Render’s website. Congressional Outlook A procedural vote to end debate and move to a... READ MORE
Tags: chip, COVID-19, FDA, Medicare quality reporting programs, risk evaluation and mitigation strategies, Telehealth
[03/21/20]
Posted on March 21, 2020 in COVID-19 Daily Updates
Published by: Hall Render
Saturday, March 21 Recap Note – We believe this is the most up-to-date information available at this time, but it is subject to change as circumstances warrant. Also, all finalized resources can be found on the COVID-19 Resource Center page of Hall Render’s website. Congressional Outlook After 12 hours of negotiation on Friday, Republicans and Democrats... READ MORE
Tags: 340B, CARES Act, Cepheid Xpert Xpress SARS-CoV-2 test, COVID-19, FDA, HIPAA, OCR, Telehealth
[03/19/20]
Posted on March 19, 2020 in COVID-19 Daily Updates, Health Law News
Published by: Hall Render
Thursday, March 19 Recap Note – We believe this is the most up-to-date information available at this time, but it is subject to change as circumstances warrant. Also, all finalized resources can be found on the COVID-19 Resource Center page of Hall Render’s website. Congressional Outlook Senate Republicans released the attached proposal for the third COVID-19... READ MORE
Tags: COVID-19, Elective Surgery, Family and Social Services Administration, FDA, stimulus package, Telehealth
[03/19/20]
Posted on March 19, 2020 in Health Law News
Published by: Hall Render
On March 18, 2020, the FDA issued FDA Guidance on Conduct of Clinical Trials of Medical Products during COVID-19 Pandemic that provides guidance for Sponsors, Clinical Investigators and Institutional Review Boards (“IRBs”) on how to address disruptions in the conduct of clinical trials (“Trials”) as a result of COVID-19. COVID-19 Disruptions to Clinical Trials... READ MORE
Tags: Clinical Investigators, Clinical Trials, COVID-19, FDA, Institutional Review Boards, Sponsors
[03/18/20]
Posted on March 18, 2020 in COVID-19 Daily Updates, Health Law News
Published by: Hall Render
Wednesday, March 18 Update Note – We believe this is the most up-to-date information available at this time, but it is subject to change as circumstances warrant. Also, all finalized resources can be found on the COVID-19 Resource Center page of Hall Render’s website. Congressional Outlook Sen. Mitch McConnell (R-KY) reversed course and the Senate passed... READ MORE
Tags: COVID-19, Elective Surgery, Family and Social Services Administration, FDA, stimulus package, Telehealth
[02/26/20]
Posted on February 26, 2020 in Health Law News
Published by: Hall Render
Pharmacogenetic Testing and the FDA’s 2018 Warning The advent of direct-to-consumer genetic testing has yielded an explosion in the development of various types of genetic tests for clinical treatment and diagnostic purposes. These tests include pharmacogenetic tests, which are used to better understand the role genetics play in an individual patient’s reaction to certain... READ MORE
Tags: FDA, Food & Drug Administration, laboratory-developed tests, LDT, Pharmacogenetic Testing
[02/26/20]
Posted on February 26, 2020 in Health Law News
Published by: Hall Render
It is no secret why the novel coronavirus (“2019-nCoV”) outbreak in Wuhan City, Hubei Province, China quickly raised health concerns on an international scale. The coronavirus family contains member viruses with a similarly sinister and deadly past; viruses that seemingly appeared out of nowhere and rapidly spread. For example, two betacoronaviruses were the culprits... READ MORE
Tags: 2019-nCoV, cdc, Centers for Disease Control, Coronavirus, FDA, Food & Drug Administration, MERS, SARS
[01/27/20]
Posted on January 27, 2020 in HR Insights for Health Care
Published by: Hall Render
The USDA Hemp Producer License Rule and Framework On October 31, 2019, the United States Department of Agriculture (“USDA”) published an interim final rule[1] with request for comments in the Federal Register regarding hemp production (“USDA Hemp Rule” or the “Interim Final Rule”).[2] The USDA Hemp Rule establishes a federal hemp producer license and... READ MORE
Tags: CBD, Drug Enforcement Agency, FDA, Food and Drug Administration, Hemp, Hemp Producer License, THC, USDA Hemp Rule
[10/25/19]
Posted on October 25, 2019 in Health Law News
Published by: Hall Render
The centuries-old practice of homeopathic medicine, which has been the subject of much controversy and debate for nearly the entire length of its existence, may finally be going to the mat with the Food & Drug Administration (“FDA”). Amidst growth in the homeopathic products industry and associated concerns with their safety, efficacy and quality,... READ MORE
Tags: CGMP, Current Good Manufacturing Practices, FDA, FDCA, homeopathic medicine
[10/24/19]
Posted on October 24, 2019 in Health Law News
Published by: Hall Render
It isn’t only the U.S. Food & Drug Administration (“FDA”) and Drug Enforcement Agency (“DEA”) that are interested in all things cannabis. Today, the FDA followed earlier warning letters[1] by posting yet another press release regarding an October 10, 2019 warning letter that was issued jointly by the FDA and the Federal Trade Commission... READ MORE
Tags: Cannabidiol, Cannabis, DEA, FDA, Federal Trade Commission Act, Food & Drug Administration